Table 8.
Study name | Study groups with number of new infections | Risk (R) | Risk ratio (RR) (95% CI) | P value | Interpretation for the RR values |
---|---|---|---|---|---|
Sawa et al., 2013 [34] | DP (n/N): 3/134 AL (n/N): 23/145 |
0.022 0.159 |
0.141 (0.043–0.459) |
0.001 | There has been 85.9% reduction in new infection associated with DP treatment. Highest plausible reduction is 95% while lowest is 54% defined by the 95% CI. The reduction is statistically significant. |
| |||||
Yeka et al., 2008 [35] | DP (n/N): 16/215 AL (n/N): 30/199 |
0.074 0.151 |
0.494 (0.278–0.878) |
0.016 | There was 50.6% reduction in risk to acquire new falciparum infection in favour of DP treatment and the reduction is statistically significant. |
| |||||
Bassat et al., 2009 [32] | DP (n/N): 122/1038 AL (n/N): 105/510 |
0.118 0.206 |
0.571 (0.450–0.725) |
<0.001 | This result shows 42.9% reduction in risk of getting new infections with falciparum and the reduction was in favour of DP and is statistically significant. The lowest plausible reduction is 27.5% while the highest is 55% as defined by the 95% CI of the RR. |
| |||||
Kamya et al., 2007 [30] | DP (n/N): 77/211 AL (n/N): 79/210 |
0.365 0.376 |
0.970 (0.756–1.244) |
0.811 | DP treatment was associated with only 3% risk reduction for new infection and the reduction is statistically insignificant. |